Overview

Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

Status:
Unknown status

Trial end date:
2020-11-29

Target enrollment:

Participant gender:

Summary

Patients with ER+/HER2- breast cancer (presumably the luminal A subtype) could potentially avoid the standard chemotherapy use. Letrozole Plus Low-Dose Metronomic Capecitabine may offer similar efficacy and less toxicity to standard chemotherapy in ER+/HER2- breast cancer patients.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Guangdong General Hospital
Guangdong Provincial People's Hospital

Treatments:

Capecitabine
Cyclophosphamide
Docetaxel
Epirubicin
Letrozole